Hypoglossal nerve stimulation (HGNS) therapy has become a more frequently employed tool in the treatment of obstructive sleep apnea since its approval by the U.S. Food and Drug Administration in 2014. One of the benefits of HGNS therapy is the low morbidity associated with the procedure.
HNS was approved by the U.S. Food and Drug Administration in 2014 as a treatment option for patients with moderate to severe OSA who cannot tolerate CPAP.
Hypoglossal Nerve Stimulator therapy is an effective and safe surgical option for patients with moderate to severe OSA who cannot tolerate PAP therapy.
The weight loss drug craze of the last couple of years brings important considerations for otolaryngologists, including how to manage gastric emptying before procedures for patients taking the medications and the possibility of the drugs being a new option for obstructive sleep apnea patients.
Physicians must recognize that the validity and accuracy of the smartphone apps are unknown.
Patients with CPAP-intolerant refractory sleep apnea confirmed by polysomnography should be offered a drug-induced sleep endoscopy (DISE) with the potential for directed surgery.
Screening for depression in patients with OSA would be worthwhile because there is a high rate of comorbidity, and both are intertwined in their pathophysiology and management.
Screening for depression in patients with OSA would be worthwhile because there is a high rate of comorbidity.
vHIT provides information complementary to other available vestibular tests and may be a key part of evaluating suspected peripheral vestibular deficits.
Recent studies have suggested a possible unique link between loud snoring and carotid artery stenosis, even in patients without OSA or with only very mild disease.